Monte Rosa Therapeutics (GLUE) Shares Outstanding (2020 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly Shares Outstanding (Entity) of $84.3 million for Q1 2026, up 2.65% year-over-year from $82.1 million in Q1 2025, and up 1.51% quarter-over-quarter from $83.1 million in Q4 2025.
Monte Rosa Therapeutics (GLUE) Shares Outstanding (2020 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Shares Outstanding (Entity) history runs 7 years deep, the most recent figure standing at $84.3 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 2.65% year-over-year to $84.3 million; the TTM figure through Mar 2026 stood at $84.3 million (up 2.65% YoY), while the FY2025 annual figure was $83.1 million, up 35.06% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $84.3 million, up from $83.1 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $84.3 million in Q1 2026, with the low at $46.6 million in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $50.2 million (2024), against an average of $62.3 million.
- The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Entity) surged 2607.78% in 2022, then grew 0.47% in 2025.
- Monte Rosa Therapeutics' Shares Outstanding (Entity) stood at $49.4 million in 2022, then climbed by 1.43% to $50.2 million in 2023, then increased by 22.63% to $61.5 million in 2024, then jumped by 35.06% to $83.1 million in 2025, then advanced by 1.51% to $84.3 million in 2026.
- Business Quant data shows GLUE's Shares Outstanding (Entity) at $84.3 million in Q1 2026, $83.1 million in Q4 2025, and $82.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Monte Rosa Therapeutics | 1.32 Bn | 688.11 Mn | - | 101.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 101.48 Mn |
| Mar 31, 2026 | 99.88 Mn |
| Dec 31, 2025 | 83.07 Mn |
| Sep 30, 2025 | 82.40 Mn |
| Jun 30, 2025 | 82.19 Mn |
| Mar 31, 2025 | 82.15 Mn |
| Dec 31, 2024 | 73.91 Mn |
| Sep 30, 2024 | 82.01 Mn |
| Jun 30, 2024 | 71.23 Mn |
| Mar 31, 2024 | 60.16 Mn |
| Dec 31, 2023 | 51.40 Mn |
| Sep 30, 2023 | 49.81 Mn |
| Jun 30, 2023 | 49.43 Mn |
| Mar 31, 2023 | 49.35 Mn |
| Dec 31, 2022 | 47.23 Mn |
| Sep 30, 2022 | 46.73 Mn |
| Jun 30, 2022 | 46.67 Mn |
| Mar 31, 2022 | 46.60 Mn |
| Dec 31, 2021 | 25.00 Mn |
| Sep 30, 2021 | 45.99 Mn |